Form 8-K - Current report:
SEC Accession No. 0001193125-26-294837
Filing Date
2026-07-02
Accepted
2026-07-02 16:56:37
Documents
14
Period of Report
2026-07-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d123412d8k.htm   iXBRL 8-K 28232
2 EX-1.1 d123412dex11.htm EX-1.1 197680
3 EX-5.1 d123412dex51.htm EX-5.1 10875
7 GRAPHIC g123412dsp46.jpg GRAPHIC 12596
  Complete submission text file 0001193125-26-294837.txt   426648

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA enta-20260702.xsd EX-101.SCH 3174
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE enta-20260702_lab.xml EX-101.LAB 17233
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE enta-20260702_pre.xml EX-101.PRE 10808
18 EXTRACTED XBRL INSTANCE DOCUMENT d123412d8k_htm.xml XML 3539
Mailing Address 4 KINGSBURY AVENUE WATERTOWN MA 02472
Business Address 4 KINGSBURY AVENUE WATERTOWN MA 02472 617 607 0800
ENANTA PHARMACEUTICALS INC (Filer) CIK: 0001177648 (see all company filings)

EIN.: 043205099 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-35839 | Film No.: 261152573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)